iPAX‑2 Trial of TLX101 TX in First‑Line Glioblastoma Finishes Enrollment and Locks In Dosing Schedule
iPAX‑2 Trial of TLX101 in First‑Line Glioblastoma Hits Full Enrollment and Dosing Confirmation
BioNTech Navigates Shifting Tides: Q1 2026 Showcases Pipeline Progress Amidst Revenue Recalibration
A New Chapter in Oncology: Telix Unveils Cutting-Edge Manufacturing Facility in Japan